Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026 - SGMT News | RalliesSagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
S
SGMT• Phase 3 trial update
- Sagimet Biosciences advances AURORA U.S. Phase 3 trial of denifanstat in acne toward patient enrollment in Q4 2026.
- Patient screening for the AURORA Phase 3 trial is set to begin in October 2026.
- All clinical trial sites have been identified and a CRO has been retained for the AURORA Phase 3 trial.
- The company anticipates submitting an NDA upon completion of the 12-week phase of the study.
